Kelsey Ramsden, the President, and CEO of Mind Cure Health Inc. sheds light on the advancements Mind Cure is currently making.
Similar Posts
Interview with Matt Zemon, Co-Founder, Psychable
In our conversation with Matt, we tackle a variety of extremely important and highly-relevant subject matters such as how technology can be utilized to enhance the community of psychedelic healing, conscious capitalism, corporate responsibility, and how companies like Psychable are willing to go out of their way to connect with investors who are motivated not only by profit, but a company’s ability to contribute to the greater good of humanity.
![Investing in Psychedelic Stocks 101 [ Interview With The Medicine Of Being Human]](https://psychedelicspotlight.com/wp-content/uploads/2022/06/maxresdefault-34-600x338.jpeg)
Investing in Psychedelic Stocks 101 [ Interview With The Medicine Of Being Human]
Hello Psychedelic Investors! As I mentioned in the previous episode of the Psychedelic Investor, last week I had my first ever interview with the wonderful Sena who is interested in creating a resource for those new to investing in psychedelic stocks and investing in stocks in general.
For those interested in the basics on psychedelic investing, you can watch the entire video on:
The Medicine of Being Human :https://www.youtube.com/watch?v=p3d_t4GYG14&t=599s&ab_channel=TheMedicineofBeingHuman
#PsychedelicStocks #MindMed #ThePsychedelicInvestor
I hope you guys found some value in this and I’ll keep you posted for more changes!
Remember to Like, Subscribe, and SMASH that notifications bell to keep up to date on all the latest Psychedelic Stocks news!
Follow us on social media! 🙌
Instagram: @psychedelicinvestor
Facebook: @thepsychedelicinvestor
Music: www.bensound.com
DISCLAIMER: I am not a financial adviser nor a CPA. These videos are for educational and entertainment purposes only. Investing of any kind involves risk. While it is possible to minimize risk, your investments are solely your responsibility. It is imperative that you conduct your own research. I am merely sharing my opinion with no guarantee of gains or losses on investments.
Will MindMed Partner With Johnson & Johnson for 18MC? ( MNMD & J&J In the Speculation Zone)
What’s up Psychedelic Investors? We all know that MindMed (MNMD / MMED) has been talking about eventually finding partners in the pharmaceuticals industry, but who will be that partner? One persistent Reddit theory posits that it will be none other than Johnson & Johnson. Could this just be a rumor? Perhaps. But depending on how you look at it, there is either some evidence for this theory…or some coincidences.
MindMed is a psychedelic medicines/psychedelic therapy company that is attempting to treat addiction, depression, anxiety and more with LSD, psilocybin (magic mushrooms), 18MC, and other psychedelics. But in order to scale up, they may need the expertise and global reach of a company like JNJ.
MindMed stock (MNMD / MMED) has been quiet for a while now, could a partnership with JNJ be exactly what the company needs? Will MindMed stock go up? Is MindMEd a good investment? Only time will tell!
Enjoy the episode!
Follow us on social media! 🙌
Instagram: @thepsychedelicinvestor
Facebook: @thepsychedelicinvestor
Want to collaborate? Send us an email at:
thepsychedelicinvestor@gmail.com
Music from:
www.bensound.com
Video editing: @themyaholy
Check out our Benziga discounts
https://benzinga.grsm.io/jameshallifax1834
https://benzinga.grsm.io/thepsychedelicinvestor
DISCLAIMER: I am not a financial adviser nor a CPA. These videos are for educational and entertainment purposes only. Investing of any kind involves risk. While it is possible to minimize risk, your investments are solely your responsibility. It is imperative that you conduct your own research. I am merely sharing my opinion with no guarantee of gains or losses on investments.
All of the information in this video is public information that James (The Psychedelic Investor) believes to be reliable but it is not guaranteed to be 100% accurate and as such should not be used as advice. Any opinions or thoughts from James (The Psychedelic Investor) are subject to change.
#MindMed #JNJ #MNMD
NEW MindMed MDMA trials, Compass Pathways Patent, Small Pharma DMT Trials Begins | MNMD, CMPS, DMT
NEW MindMed MDMA trials, Compass Pathways Patent, Small Pharma DMT Trials Begins | MNMD, CMPS, DMT
What’s up psychedelic investors! We have been seeing a lot of red in the last few months. Companies like MindMed (MNMD: NASDAQ) (MMED:NEO), Compass Pathways (CMPS: NASDAQ) &Small Pharma ( OTC: DMTTF) ( CVE: DMT) have had huge news in the last week. So in this episode we’ll be covering the major news surrounding these psychedelic stocks!
Enjoy the episode!
Follow us on social media! 🙌
Instagram: @thepsychedelicinvestor
Facebook: @thepsychedelicinvestor
Want to collaborate? Send us an email at:
thepsychedelicinvestor@gmail.com
Music from:
www.bensound.com
Video editing: @themyaholy
DISCLAIMER: I am not a financial adviser nor a CPA. These videos are for educational and entertainment purposes only. Investing of any kind involves risk. While it is possible to minimize risk, your investments are solely your responsibility. It is imperative that you conduct your own research. I am merely sharing my opinion with no guarantee of gains or losses on investments.
All of the information in this video is public information that James (The Psychedelic Investor) believes to be reliable but it is not guaranteed to be 100% accurate and as such should not be used as advice. Any opinions or thoughts from James (The Psychedelic Investor) are subject to change.
#MindMed #CompassPathways #PsychedelicStocks
![How Do our Genes Affect an LSD TRIP?? New MindMed Study [ MMED / MNMD ]](https://psychedelicspotlight.com/wp-content/uploads/2022/06/maxresdefault-126-600x338.jpeg)
How Do our Genes Affect an LSD TRIP?? New MindMed Study [ MMED / MNMD ]
Does our Genetic makeup influence our LSD trip?
Hey psychedelic Investors! MindMed ( MMED/MNMD/MMQ ) recently published a study in Nature Scientific Reports examining the different variations in our genes and how they affect one’s experience during an LSD trip.
The results are leading us to infer that, soon, we might be able to predict the strength, duration and perhaps even the subjective experience one undergoes when taking LSD based on certain genes that we possesses.
If we’re able to do that, how will this affect LSD’s medical uses in therapy setting?
Can we use this knowledge to move towards personalized dosing, where each individual will receive a different dose level for the same procedure, based on what their genetic code tells the therapist?
We will answer these questions in today’s episode .
We will also take a deep dive into the LSD study itself and explain why the findings are important for the future of psychedelic-assisted psychotherapy.
Remember to Like, Subscribe, and SMASH that notifications bell to keep up to date on all the latest Psychedelic Stocks news!
Follow us on social media! 🙌
Instagram: @psychedelicinvestor
Email: thepsychedelicinvestor@gmail.com
Facebook: @thepsychedelicinvestor
editing: @themyaholy
Music: www.bensound.com
https://benzinga.grsm.io/jameshallifax1834
https://benzinga.grsm.io/thepsychedelicinvestor
DISCLAIMER: I am not a financial adviser nor a CPA. These videos are for educational and entertainment purposes only. Investing of any kind involves risk. While it is possible to minimize risk, your investments are solely your responsibility. It is imperative that you conduct your own research. I am merely sharing my opinion with no guarantee of gains or losses on investments.
All of the information in this video is public information that James (The Psychedelic Investor) believes to be reliable but it is not guaranteed to be 100% accurate and as such should not be used as advice. Any opinions or thoughts from James (The Psychedelic Investor) are subject to change.
#MindMed #MindMedNews #MindMedstock
Fireside Project
Fireside Project is excited to launch on April 14th as a 24/7 support hotline